With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Remember on Friday (me neither) when everyone was minding their own business waiting for the work/school/whatever day to be over and Vanity Fair wandered in with a bombshell report on Meghan ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $725.72. According to ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

In the trailer for her postponed Netflix series, With Love, Meghan, which ties in with the upcoming launch of her lifestyle brand, American Riviera Orchard, the Duchess is seen baking for her ...

He reported on Prince Harry and Meghan's royal wedding from inside Windsor Castle. He graduated from the University of East Anglia. Languages: English. You can find him on Twitter at @jack_royston ...

Prince Harry and Meghan Markle have reportedly dismissed a string of bombshell claims made against them in a brutal magazine article. Vanity Fair, a glossy US magazine which traditionally favours ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.